Gaiectin-3 as a Potential Prognostic Biomarker for COVID-19 Disease: A Case-Control Study

Basit Öğe Kaydı
dc.authoridKoseler, Aylin/0000-0003-4832-0436
dc.contributor.authorKarsli, Emre
dc.contributor.authorMetin, Damla Anabarli
dc.contributor.authorCanacik, Omer
dc.contributor.authorSabirli, Ramazan
dc.contributor.authorKaymaz, Buse
dc.contributor.authorKurt, Ozgur
dc.contributor.authorKoseler, Aylin
dc.date.accessioned2024-09-29T16:10:16Z
dc.date.available2024-09-29T16:10:16Z
dc.date.issued2022
dc.departmentKarabük Üniversitesien_US
dc.description.abstractBackground Recent studies have investigated the importance of Galetin-3 in inflammation, fibrosis, cell proliferation, cardiac disease, diabetes, and tumor formation. Aims This study aims to investigate the role of the Galectin-3 level in the diagnosis of COVID-19 pneumonia and the value of the Galectin-3 level in predicting the clinical course of the patient. Methods This study employed a prospective, case-control study design and was conducted at Bakircay University Cigli Training and Research Hospital. A total of 100 patients (40 had moderate and 60 had severe/critical COVID-19 disease according to World Health Organisation guidelines) and 50 non-symptomatic healthy volunteers participated in the study. Blood samples were taken from patients at the time of hospital admission, after which serum was isolated. Following the isolation of serum, Galectin-3 levels were evaluated using the enzyme-linked immunosorbent assay (ELISA) method. Results The serum Galectin-3 level was measured as 13.57 (10.9-16.4) ng/mL in the control group, 13.52 (10.69-16.6) ng/mL in the moderate disease group, and 11.65 (6.09-14.33) ng/mL in the severe/critical disease group. Serum Galectin-3 levels were significantly lower in the severe/critical disease group compared to the control and moderate disease groups (p=0.001 and p=0.019, respectively). Using ROC analysis, a larger area under the curve (AUC) for the serum Galectin-3 levels of the control group (AUC-0.622, 95% CI =0.529-0.714; p=0.015) was calculated compared to the COVID-19 patient group for the diagnosis of COVID-19 disease. The Galectin-3 level was found to be 75% sensitive and 50% specific at a cut-off level of 11.3 ng/mL in predicting the need for ICU treatment. Conclusion Galectin-3 levels may be a beneficial biomarker in predicting the clinical severity of COVID-19 disease when used in conjunction with other known biomarkers, at the time of admission to the emergency department (ED).en_US
dc.identifier.doi10.7759/cureus.28805
dc.identifier.issn2168-8184
dc.identifier.issue9en_US
dc.identifier.pmid36225452en_US
dc.identifier.urihttps://doi.org/10.7759/cureus.28805
dc.identifier.urihttps://hdl.handle.net/20.500.14619/8079
dc.identifier.volume14en_US
dc.identifier.wosWOS:000888596900022en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringernatureen_US
dc.relation.ispartofCureus Journal of Medical Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectinflamationen_US
dc.subjectclinical infectious diseaseen_US
dc.subjectcovid-19 pneumoniaen_US
dc.subjectcovid-19en_US
dc.subjectgalectin-3en_US
dc.titleGaiectin-3 as a Potential Prognostic Biomarker for COVID-19 Disease: A Case-Control Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu